{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:45:25Z","timestamp":1786999525361,"version":"build-2736575974"},"reference-count":30,"publisher":"Cambridge University Press (CUP)","issue":"S20","license":[{"start":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T00:00:00Z","timestamp":1415318400000},"content-version":"unspecified","delay-in-days":3263,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Objective<\/jats:bold>\n                    : Assess the long-term safety and effectiveness of mixed amphetamine salts extended release (MAS XR) in adults with attention-deficit\/hyperactivity disorder (ADHD) combined subtype.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods<\/jats:bold>\n                    : A 24-month, open-label extension of a 4-week, multicenter, double-blind, placebo-controlled, parallel-group, forced\u2013dose-escalation study of MAS XR in adults (\u2265 18 years of age) with ADHD. The 223 enrolled subjects started treatment at 20 mgl day for 1 week, with subsequent titration up to 60 mgl day for optimal therapeutic effects. At monthly visits, efficacy was assessed based on the ADHD Rating Scale IV (ADHD-RS-N). Safety assessments included spontaneously reported adverse events, laboratory assessments, and monitoring of vital signs.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Findings<\/jats:bold>\n                    : ADHD symptoms significantly improved for all subjects as measured by change from baseline in mean ADHD-RS-IV total scores (-7.2\u00b113.04 unit points; P&lt;.001); this was sustained for up to 24 months. The most common treatment-related adverse events were dry mouth (43% of subjects reporting at least one occurrence), infection (33%), insomnia (32%), anorexia\/decreased appetite (32%), headache (30%), and nervousness (26%). Most adverse events were mild to moderate in intensity.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion<\/jats:bold>\n                    : Treatment with MAS XR 20\u201360 mgl day for adult ADHD was generally well tolerated and was associated with sustained symptomatic improvement for up to 24 months.\n                  <\/jats:p>","DOI":"10.1017\/s1092852900002406","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T00:47:04Z","timestamp":1470098824000},"page":"16-25","source":"Crossref","is-referenced-by-count":58,"title":["Long-Term Safety and Effectiveness of Mixed Amphetamine Salts Extended Release in Adults With ADHD"],"prefix":"10.1017","volume":"10","author":[{"given":"Joseph","family":"Biederman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy E.","family":"Wilens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H.","family":"Weisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie C.","family":"Read","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Tulloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2014,11,7]]},"reference":[{"key":"S1092852900002406_ref024","volume-title":"Adderall, XR dosed once daily in adult patients with, ADHD","author":"Weisler","year":"2003"},{"key":"S1092852900002406_ref002","doi-asserted-by":"publisher","DOI":"10.1002\/mrdd.10036"},{"key":"S1092852900002406_ref001","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.5.619"},{"key":"S1092852900002406_ref010","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.5.816"},{"key":"S1092852900002406_ref028","volume-title":"The Assessment of the Potential for, QT Interval Prolongation by Non-cardiovascular Medicinal Products","year":"1997"},{"key":"S1092852900002406_ref029","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1017\/S1092852900014115","article-title":"Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in adolescents with, ADHD","volume":"10","author":"Biederman","year":"2005","journal-title":"CNS Spectr"},{"key":"S1092852900002406_ref013","volume-title":"A controlled study of functional impairments in 500 ADHD adults","author":"Faraone","year":"2004"},{"key":"S1092852900002406_ref017","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.58.8.775"},{"key":"S1092852900002406_ref006","unstructured":"6. United States Census Bureau: Census 2000 Summary File 4- Available at: http:\/\/factfinder.census.gov. Accessed August 16, 2004."},{"key":"S1092852900002406_ref008","doi-asserted-by":"publisher","DOI":"10.3109\/10673229409017099"},{"key":"S1092852900002406_ref003","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199710001-00007"},{"key":"S1092852900002406_ref016","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199906000-00009"},{"key":"S1092852900002406_ref004","volume-title":"Prevalence of adult, ADHD in the United States: results from the National Comorbidity Survey Replication (NCS)","author":"Kessler","year":"2004"},{"key":"S1092852900002406_ref030","volume-title":"Dose and time response of atomoxetine use in adult, ADHD","author":"Adler","year":"2004"},{"key":"S1092852900002406_ref005","volume-title":"Prevalence of adult, ADHD in the United States","author":"Faraone","year":"2004"},{"key":"S1092852900002406_ref007","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(00)00889-1"},{"key":"S1092852900002406_ref009","first-page":"3","article-title":"Impact of comorbidity in adults with attention-deficit\/hyperactivity disorder","volume":"65","author":"Biederman","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"S1092852900002406_ref011","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2003.12.003"},{"key":"S1092852900002406_ref012","first-page":"10","article-title":"Major life activity and health outcomes associated with attentiondeficit\/ hyperactivity disorder","volume":"63","author":"Barkley","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"S1092852900002406_ref014","volume-title":"The costs associated with attention-deficit\/hyperactivity disorder in adults","author":"Lage","year":"2004"},{"key":"S1092852900002406_ref022","volume-title":"Long-term efficacy of extended-release dexmethylphenidate in adult, ADHD","author":"Adler","year":"2004"},{"key":"S1092852900002406_ref019","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000157550.94702.a2"},{"key":"S1092852900002406_ref021","doi-asserted-by":"publisher","DOI":"10.1542\/peds.110.2.258"},{"key":"S1092852900002406_ref018","doi-asserted-by":"publisher","DOI":"10.1097\/01.CHI.0000046814.95464.7D"},{"key":"S1092852900002406_ref023","volume-title":"Open-label study of, OROS methylphenidate in the treatment of adults with, ADHD not otherwise specified (NOS)","author":"Biederman","year":"2005"},{"key":"S1092852900002406_ref020","doi-asserted-by":"publisher","DOI":"10.1097\/01.CHI.0000046863.56865.FE"},{"key":"S1092852900002406_ref025","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2000"},{"key":"S1092852900002406_ref026","volume-title":"ADHD Rating Scale, IV: Checklists, Norms, and Clinical Interpretation","author":"DuPaul","year":"1998"},{"key":"S1092852900002406_ref027","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000107251.49515.c2"},{"key":"S1092852900002406_ref015","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1995.03950180020004"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852900002406","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T15:40:04Z","timestamp":1556898004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852900002406\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":30,"journal-issue":{"issue":"S20","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["S1092852900002406"],"URL":"https:\/\/doi.org\/10.1017\/s1092852900002406","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12]]}}}